The scientific wonder of stem cell research and its implications for medicine have come a long way in the last decade: At Children’s Hospital of Philadelphia Research Institute, our investigators’ innovative use of stem cell science to approach complex pediatric conditions continues to inspire for their potential to improve outcomes in children’s health. In our latest news roundup, learn about novel stem cell research from our Cancer Center and Division of Urology that aims to preserve the future fertility of boys who undergo childhood cancer treatment. Discover a new project co-led by a CHOP neurology researcher that takes a stem cell approach to restore vision cells in blind dogs.
PolicyLab hosted a 10th anniversary celebration Oct. 22 that its attendees won’t forget. After more than a decade of working to inform policies impacting children’s health, the Center of Emphasis at Children’s Hospital of Philadelphia gathered regional and national leaders alongside clinicians, academics, and community collaborators at the National Museum of American Jewish History in Philadelphia to discuss the future of children’s health policy and practice.
With the release of over 200 genomic tumor models spanning 25 different types of childhood cancer, researchers may now have the ability to skip lengthy preclinical work in their development of novel treatments. With funding from Alex’s Lemonade Stand Foundation (ALSF), the Pediatric Preclinical Testing Consortium (PPTC) announced their data sets will now be made available to any qualified academic petitioner — a move that John Maris, MD, oncologist at Children’s Hospital of Philadelphia Cancer Center and principal investigator of the PPTC’s CHOP site, believes is the first of its kind.
Our breakthrough research at Children’s Hospital of Philadelphia Research Institute made headlines in both popular science media outlets and prominent scientific journals alike, from advances in detecting sepsis, to pioneering work in prenatal gene editing, to the future of genomic medicine. Read on to learn more about how our scientists stay at the cutting-edge of their fields by approaching pediatric medicine inventively, whether it’s by developing the most effective alerts in emergency medicine, modernizing genetic testing models to keep up with an accelerating pace of discovery, and beyond.
Four scientists from Children’s Hospital of Philadelphia’s Cancer Center received grants from the St. Baldrick’s Foundation to conduct research projects to improve outcomes for children with cancer.
The top private funder of childhood cancer research grants in the U.S., St. Baldrick’s awarded researchers and institutions around the nation a total of $19.1 million this year in what the charitable organization called “its biggest grant cycle of 2018.” In all, St. Baldrick’s has funded more than $253 million in childhood cancer research grants since 2005.
With an enterprising career spanning 50 years in basic and clinical immunology and more than 500 publications, Steven D. Douglas, MD, had the honor of presenting the 25th Herman and Gertrude Silver Lecture, in which he reviewed major milestones in the field of pediatric HIV/AIDS and shared his optimism that paradigm shifts and new discoveries are ahead.
Children’s Hospital of Philadelphia’s Ignacio Tapia, MD, received the inaugural Carole L. Marcus Outstanding Achievement Award from the American Thoracic Society (ATS), named in honor of his CHOP colleague who was a leader in pediatric sleep medicine research.
“It was a great honor to receive this award named after my mentor,” Dr. Tapia said. “I am working hard every day to live up to the expectations.”
For more than 20 years, researchers at Children’s Hospital of Philadelphia and the University of Pennsylvania have been at the forefront of taking a system perfected by nature — a virus — and transforming it into breakthrough gene therapies for rare single-gene diseases. CHOP was the first pediatric research institution to develop chimeric antigen receptor T cell (CAR-T) therapy for acute lymphoblastic leukemia. In this approach, viral vectors are used to modify a patient’s own T cells, training them to track down and eliminate the circulating cancer cells.
As we move full-speed ahead into fall, the new season brings with it a handful of headlines from our researchers at Children’s Hospital of Philadelphia. This week, we share the latest news about investigators who have been recognized for their research legacies and for their current cutting-edge work, from discoveries in the basic and clinical science of HIV/AIDS, to the development of learning health system-based training in outcomes research, to the design of innovative approaches to childhood cancer.